Catalent
As on 18 Dec, 2024 | 02:29 IST
| Open | 63.49 |
| Previous Close | 63.48 |
| Beta | -0.03 |
| High | 63.50 |
| Low | 63.47 |
| TTM EPS See historical trend | 0.49(-14.04% YoY) |
| 52 Week High | 63.50 |
| 52 Week Low | 42.11 |
| TTM PE See historical trend | 129.57(High PE) |
| Mkt. Cap ($ Billion) | 11.48 |
| Dividend Yield | -- |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 63.25 |
| 10 | 62.65 |
| 20 | 61.6 |
| 50 | 60.41 |
| 100 | 60.1 |
| 200 | 58.15 |
Returns
| 1 Week | 0.56% | |
| 1 Month | 8.03% | |
| 3 Months | 5.41% | |
| YTD | 41.31% | |
| 1 Year | 51.56% | |
| 3 Years | -49.36% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 988.85 | 0.38 | 940.17 | 40.85 | 24.21 | 0.58 | 1,133.95/623.99 | -4.92 | Very Bearish |
| J&J | 243.19 | 0.69 | 586.11 | 22.52 | 10.80 | 2.50 | 251.71/143.68 | 0.02 | Bullish |
| Merck | 115.43 | -0.16 | 292.37 | 12.87 | 8.97 | 3.12 | 125.14/73.35 | -4.89 | Bullish |
| UnitedHealth | 285.49 | 1.21 | 263.22 | 17.51 | 16.31 | 2.64 | 605.47/234.61 | -2.68 | Bearish |
| Thermo Fisher Scientific | 470.00 | 1.21 | 179.22 | 20.55 | 22.87 | 0.30 | 643.99/385.72 | -6.90 | Very Bearish |
Market news
- US stocks close down as oil spikes 12%, job market weakensMarch 7, 2026 9:27 AM
- Wall Street ends higher after Supreme Court rules against Trump tariffsFebruary 21, 2026 8:06 AM
- S&P 500 ends up slightly as tech dips, inflation coolsFebruary 14, 2026 9:22 AM
- Dow Jones Industrial Average breaks 50,000 level for first timeFebruary 7, 2026 9:16 AM
About the company
Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.